Latest

Headliner: Scientist CEO sets sights on Sierra Leone

Headliner: Scientist CEO sets sights on Sierra Leone

Thomas Sack, President and CEO, MRIGlobal

Five things for pharma marketers to know: Friday, January 23

Five things for pharma marketers to know: Friday, January 23

Express Scripts takes aim at high-priced cancer drugs; FDA panel recommends approval for Astellas orphan drug; GSK Ebola Vaccine could touch down in Liberia as early as next week.

Actavis CEO touts his acquisition strategy

Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.

Rx painkillers increase risk of birth defects: CDC

The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

The biotech exec speaks about the global launch of his firm's lead product, Duchenne drug Translarna.

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.

Five things for pharma marketers to know: Thursday, January 22

Five things for pharma marketers to know: Thursday, January 22

Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.

Novartis psoriasis drug approval could upend market

Novartis psoriasis drug approval could upend market

A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.

Merck to end US Victrelis distribution this year

The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.

Nurse practitioner workforce has just about doubled

Marketers may want to dust off plans to create NP-centric materials.

Agency Spotlight



Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters